This was the stock's fourth consecutive day of losses.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Eli Lilly? Access our full analysis report here ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Our analysis of options history for Eli Lilly (NYSE:LLY ... is up 4.39% at $829.0. RSI indicators hint that the underlying stock may be approaching overbought. Next earnings are expected to ...

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance, at -26.5% and -6.7%, ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly CEO Dave ... to treat obesity. Lilly will seek approval from the Food and Drug Administration for the medicine. Despite the strong Q1 report, Lilly stock slipped Thursday morning before ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Still, this was a softer quarter. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Eli Lilly? Access our full ...